Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection Running title: Rituximab modulates CD20 from the B-cell surface
نویسندگان
چکیده
From: Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. Biomedical Imaging Unit, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. Cancer Research UK Cancer Centre, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
منابع مشابه
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 monoclonal antibodies (mAbs) are continuously being sought. Here we demonstrate that type II (tositumomab-like) ant...
متن کاملتولید آنتی بادی تک زنجیرهای انسانی شده ضد مارکر CD20 در E.coli
Background and Objectives: Rituximab is an anti-CD20 chimeric monoclonal antibody widely used for the treatment of malignant B cells lymphoma. However, the immunogenicity of murine-derived monoclonal antibodies and the large size of full length antibodies restrict cancer immunotherapy. Humanized single chain antibodies can be a solution and a promising alternative for application in immunothera...
متن کاملAntigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab, a type II mAb, lacks the ability to redistribute into lipid rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC). We previous...
متن کاملتولید انبوه آنتیبادی مونوکلونال علیه پپتید خارج سلولی CD20 و ارزیابی اتصال اختصاصی آن به سلولهای بیانکننده CD20
Background & Aims: Nowadays, by advent of hybridoma technology in monoclonal antibodies production various cell markers could be evaluated in malignant and non-malignant cells. CD20, non-glycosylated phosphoprotein is as an ideal marker in leukemia and B-cell lymphoma diagnosis which is expressed on more than 95% of normal and neoplastic B-cells except for early B-cells and mature plasma. Th...
متن کاملSurface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
BACKGROUND The sensitivity of human Burkitt's lymphoma cells to rituximab (Rtx) and tositumomab (Tst) was assessed on cells expressing different levels of CD20 on surface. Cells that harbor low CD20 levels may resists against therapeutics response to CD20-specific antibodies. We postulated that, radiation-induced modulation of CD20 surface levels may play a crucial and central role in determini...
متن کامل